You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Consider alternative causes before allocating acute ischaemic stroke to COVID-19
  1. Josef Finsterer
  1. Neurology & Neurophysiology Center, Vienna, Austria
  1. Correspondence to Dr Josef Finsterer, Neurology & Neurophysiology Center, 1180 Vienna, Austria; fifigs1{at}yahoo.de

https://doi.org/10.1136/jnnp-2022-329029

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with interest the excellent article by Dmytriw et al reported on a retrospective, multicenter cohort study of patients with COVID-19 with acute ischaemic stroke (AIS) admitted to stroke units in the USA and Canada between March and August 2020.1 The primary endpoint was a modified Rankin Scale (mRS) of 5–6 and the secondary endpoints were an mRS<3, ordinal RS, symptomatic intracerebral haemorrhage and complications during hospitalisation.1 It has been established that there may be an association between COVID-19-associated AIS and severe outcome or death, and that the neutrophil to lymphocyte ratio predicts morbidity and mortality.1 The study is attractive but raises concerns that need to be discussed.

    A limitation of the study is that cardiogenic sources of AIS …

    View Full Text

    Footnotes

    • Contributors The author was resposible for all required issues.

    • Funding The author has not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.